A stride forward
OSPHOS contains clodronate disodium, a bisphosphonate indicated
for the control of clinical signs associated with navicular syndrome
in horses. OSPHOS is the only FDA-approved bisphosphonate
for use in horses that is labeled for intramuscular injection.
In a clinical trial evaluating OSPHOS in 86 horses, lameness
improved in 74.7% of horses by at least one grade 56 days after
treatment. Only 9% of horses displayed clinical signs of being
uncomfortable, nervous, colicky and or pawing after receiving
OSPHOS. Less than 1% of horses experienced colic
requiring treatment.
WITH OSPHOS THE BENEFITS ARE CLEAR . . .
As with all drugs, side effects may occur. In feld studies, the most common side effects reported were signs of discomfort or
nervousness, colic, and/or pawing. OSPHOS should not be used in pregnant or lactating mares, or mares intended for breeding.
Use of OSPHOS in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not recommended.
Refer to the prescribing information for complete details or visit www.dechra-us.com.
Learn more online
www.dechra-us.com
www.equinelameness.com
Introducing OSPHOS,
the new intramuscular
injection from Dechra
Veterinary Products
Easily administered
via intramuscular
injection
Well tolerated*
in clinical trials
Proven effcacy*
at 6 months
post treatment
(866) 933-2472
Call our 24 hour Tech Support
No
Reconstitution
required
* Freedom of Information Summary, Original New Animal Drug Application, NADA 141-427, for OSPHOS. April 28, 2014.
CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian.